|
|
Article: Sangamo BioSciences Research Collaborators Awarded Grant From California Institute for Regenerative Medicine to Develop Zinc Finger Nuclease-Based Stem Cell Therapy for HIV/AIDS.
- Article from:
- AIDS Weekly
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells. The four year grant supports an innovative research project conducted by a multidisciplinary team of investigators led by John Zaia, M.D. the Aaron D. and Edith Miller Chair in Gene Therapy and chair of virology, City of Hope. The grant application entitled "Zinc Finger Nuclease-Based Stem Cell Therapy for AIDS" won the highest score of all grants CIRM received in ...
Related newspaper, magazine, and journal articles:
|
|
Article: GENE THERAPY... UNDER THE MICROSCOPE AGAIN
The Scientist;
May 9, 2005 ;
700+ words
... ... University of Pennsylvania, the news on gene therapy hasn't gotten much better. In a recent ... piece of our special feature section on gene therapy. Still, it's an inescapable fact that gene therapy saved the lives of other children in ...
|
|